DDInter1867 DDInter1925
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Triflupromazine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Triflupromazine {u} (Compound) upregulates {v} (Gene) MSMO1
MSMO1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Triflupromazine {u} (Compound) downregulates {v} (Gene) ZDHHC6
ZDHHC6 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Trifluoperazine {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Triflupromazine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Vemurafenib
Triflupromazine {u} (Compound) upregulates {v} (Gene) MSMO1
MSMO1 {u} (Gene) is downregulated by {v} (Disease) melanoma
melanoma {u} (Disease) is treated by {v} (Compound) Vemurafenib
Triflupromazine {u} (Compound) upregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) regulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Triflupromazine {u} (Compound) downregulates {v} (Gene) ZDHHC6
ZDHHC6 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Vemurafenib
Triflupromazine {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is regulated by {v} (Gene) PAN2
PAN2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Triflupromazine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is associated with {v} (Disease) melanoma
melanoma {u} (Disease) is treated by {v} (Compound) Vemurafenib
Triflupromazine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Vemurafenib (Compound)
Triflupromazine (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by Vemurafenib (Compound)
Triflupromazine (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is downregulated by Vemurafenib (Compound)
Triflupromazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may lead to a major life threatening interaction when taken with Vemurafenib
Triflupromazine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Vemurafenib (Compound)
Triflupromazine (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by melanoma (Disease) and melanoma (Disease) is treated by Vemurafenib (Compound)
Triflupromazine (Compound) upregulates ACAT2 (Gene) and ACAT2 (Gene) regulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)
Triflupromazine (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Vemurafenib (Compound)
Triflupromazine (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is regulated by PAN2 (Gene) and PAN2 (Gene) is upregulated by Vemurafenib (Compound)
Triflupromazine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is associated with melanoma (Disease) and melanoma (Disease) is treated by Vemurafenib (Compound)